Abstract

BackgroundComplex diseases are characterized by multiple subtle perturbations to biological processes. New omics platforms can detect these perturbations, but translating the diverse molecular and statistical information into testable mechanistic hypotheses is challenging. Therefore, we set out to create a public tool that integrates these data across multiple datasets, platforms, study designs and species in order to detect the most promising targets for further mechanistic studies.ResultsWe developed Mergeomics, a computational pipeline consisting of independent modules that 1) leverage multi-omics association data to identify biological processes that are perturbed in disease, and 2) overlay the disease-associated processes onto molecular interaction networks to pinpoint hubs as potential key regulators. Unlike existing tools that are mostly dedicated to specific data type or settings, the Mergeomics pipeline accepts and integrates datasets across platforms, data types and species. We optimized and evaluated the performance of Mergeomics using simulation and multiple independent datasets, and benchmarked the results against alternative methods. We also demonstrate the versatility of Mergeomics in two case studies that include genome-wide, epigenome-wide and transcriptome-wide datasets from human and mouse studies of total cholesterol and fasting glucose. In both cases, the Mergeomics pipeline provided statistical and contextual evidence to prioritize further investigations in the wet lab. The software implementation of Mergeomics is freely available as a Bioconductor R package.ConclusionMergeomics is a flexible and robust computational pipeline for multidimensional data integration. It outperforms existing tools, and is easily applicable to datasets from different studies, species and omics data types for the study of complex traits.Electronic supplementary materialThe online version of this article (doi:10.1186/s12864-016-3198-9) contains supplementary material, which is available to authorized users.

Highlights

  • In parallel to large-scale genomic projects, new computational tools are required to convert massive genomics data into biological insights that can lead to novel mechanistic hypotheses

  • MSEA is based on the notion that while it is difficult to say which marker is causal for a disease, if the markers associated with a biological process

  • Using Weighted key driver analysis (wKDA), we identified candidate key drivers in the liver and adipose tissues for each of the top six cholesterol-associated subnetworks

Read more

Summary

Introduction

In parallel to large-scale genomic projects, new computational tools are required to convert massive genomics data into biological insights that can lead to novel mechanistic hypotheses. The available methods are typically tailored for a particular combination of datasets (e.g. human genetics with gene expression, or human genetics with pathways or protein-protein interactions), lacking the flexibility to accommodate additional data types and multiple datasets from one or more species, tissues and platforms. Network approaches such as WGCNA and postgwas emphasize the detection of modules of co-operating genes, but validation experiments in the wet lab and therapeutic target selection require narrowing in on strong driver genes at the center of the module. The source code for Mergeomics is released as an R package (http://mergeomics.research.idre.ucla.edu/Download/Package/)

Methods
Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.